Exciting News: Fragmentomics by Liqomics
We are thrilled to announce that our project, Fragmentomics by LIQOMICS, has been selected as one of only 4 projects that will be supported as part of the prestigious funding program ZukunftBIO.NRW. This represents a significant milestone for us as we continue to innovate and advance the field of liquid biopsy diagnostics.
This line of our research focuses on utilizing cutting-edge technologies to study cell-free DNA fragmentation patterns, unlocking new insights into biomarker discovery and disease monitoring. This research has the potential to revolutionize precision medicine by providing non-invasive, highly accurate diagnostic solutions.
LIQOMICS specializes in the development of high-sensitivity cell-free DNA assays, with a focus on enabling precise monitoring and personalized treatments for cancer patients. Headquartered in Cologne, Germany, Liqomics provides innovative diagnostics for lymphomas and beyond.
For more information about our work or to discuss collaboration opportunities, visit our website and get in touch to see what we can offer. Together, let’s shape the future of healthcare!